Latest ANI Pharmaceuticals Inc (ANIP) Headlines
Can The Uptrend Continue for ANI Pharmaceuticals (ANIP)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 9:43AM CDT
Can The Uptrend Continue for ANI Pharmaceuticals (ANIP)?
Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
ANI Pharmaceuticals concludes public offering at USD31.00 per share
M2 - Tue Mar 11, 7:14AM CDT
US-based pharmaceutical company ANI Pharmaceuticals (NasdaqGM:ANIP) revealed on Monday that it has closed its underwritten public offering of 1,612,903 shares of its common stock.
ANI Pharmaceuticals Presents at 26th Annual ROTH Conference
PR Newswire - Mon Mar 10, 4:00PM CDT
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) presented at the 26th Annual ROTH Conference at the Ritz-Carlton at Laguna Niguel, California. On March 10, 2014 at 11:30am PDT, Arthur S. Przybyl, President and CEO, gave the presentation, which was webcast live at http://wsw.com/webcast/roth28/anip. The live webcast was archived and will be available through the prior link for 90 days through June 8, 2014.
Regulatory Approvals, Pricing of Public Offering, Stock Price Movements, and Financial Reports - Analyst Notes on Arrowhead, ANI, OraSure, Rigel, and Foundation Medicine
PR Newswire - Mon Mar 10, 11:30AM CDT
Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), OraSure Technologies, Inc. (NASDAQ: OSUR), Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), and Foundation Medicine, Inc. (NASDAQ: FMI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
ANI Pharmaceuticals Announces Closing Of Public Offering Of Common Stock
PR Newswire - Mon Mar 10, 9:45AM CDT
ANI Pharmaceuticals, Inc. (the "Company") (NASDAQ: ANIP), today announced the closing of its previously announced underwritten public offering of 1,612,903 shares of common stock, at a price to the public of $31.00 per share and for gross proceeds of $50.0 million. The shares include 210,378 shares of common stock sold pursuant to the over-allotment option granted by ANI to the underwriters, which option was exercised in full. ANI expects net proceeds of the offering will be approximately $46.8 million, after deducting underwriting commissions and other offering expenses. Oppenheimer & Co. Inc. and Roth Capital Partners acted as joint book-running managers for the offering.
ANI Pharmaceuticals Expands Generic Drug Development Agreement with Sterling Pharmaceuticals
PR Newswire - Mon Mar 10, 7:00AM CDT
ANI Pharmaceuticals, (NASDAQ: ANIP), an emerging generic pharmaceutical company, today announced that it has entered into a fee for service product development agreement for an undisclosed generic drug product with Sterling Pharmaceutical Services ("Sterling"). The product will be developed by Sterling and transferred into ANI for commercial manufacture and marketing.
RestorGenex Names Stephen M. Simes as Chief Executive Officer
GlobeNewswire - Mon Mar 10, 6:13AM CDT
RestorGenex (OTCBB:SMDID) announced today that it has named Stephen M. Simes as its Chief Executive Officer, to lead the company. Mr. Simes formerly served as vice chairman, president, and CEO at BioSante Pharmaceuticals, Inc., a publicly held pharmaceutical company focused on developing products for women's and men's health and oncology that merged with ANI Pharmaceuticals, Inc. in 2013.
ANI Pharmaceuticals to Present at 26th Annual ROTH Conference
PR Newswire - Thu Mar 06, 9:45AM CST
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that its President and Chief Executive Officer, Arthur S. Przybyl, is scheduled to present at the 26th Annual ROTH Conference at the Ritz-Carlton at Laguna Niguel, California on Monday, March 10, 2014 at 11:30 a.m. Pacific Time. Charlotte C. Arnold, Vice President and Chief Financial Officer, will also be in attendance and representing ANI. Mr. Przybyl's presentation will be webcast live at http://wsw.com/webcast/roth28/anip, and archived and available through the link through June 8, 2014.
Strength Seen in ANI Pharmaceuticals, Inc. (ANIP): Stock Soars 15.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:44AM CST
ANI Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares surge 16% on the day.
ANI Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
PR Newswire - Wed Mar 05, 8:00AM CST
ANI Pharmaceuticals, Inc. (the "Company") (NASDAQ: ANIP) today announced that it has priced a firm commitment underwritten public offering of 1,402,525 shares of the Company's common stock at a purchase price to the public of $31.00 per share, resulting in net proceeds to the Company of $43.5 million (before estimated offering expenses payable by us). Oppenheimer & Co. Inc. and Roth Capital Partners are acting as joint book-running managers for the offering. The offering is expected to close on or about March 10, 2014, subject to customary closing conditions. The Company also granted the underwriters a 30-day option to purchase up to an additional 210,378 shares. The Company expects to use the net proceeds of the offering to research, develop, commercialize and expand its drug products, to acquire complementary businesses and technologies and for working capital and general corporate purposes.
ANI Pharmaceuticals Announces Proposed Public Offering Of Common Stock
PR Newswire - Tue Mar 04, 3:50PM CST
ANI Pharmaceuticals, Inc. (the "Company") (NASDAQ: ANIP) today announced that it intends to offer its common stock in a registered public offering pursuant to its existing shelf registration statement under the Securities Act of 1933, as amended. The Company also intends to grant the underwriters of the offering an option to purchase additional shares of common stock to cover over-allotments, if any. The Company plans to use the proceeds from the offering to research, develop, commercialize and expand its drug products, to acquire complementary businesses and technologies and for working capital and general corporate purposes. Oppenheimer & Co. Inc. and Roth Capital Partners are acting as joint book-running managers for the offering.
Surging Earnings Estimates Signal Good News for ANI Pharmaceuticals (ANIP) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 7:51AM CST
ANI Pharmaceuticals could be an interesting play for investors as it is witnessing solid activity on the earnings estimate revision front
Nasdaq stocks posting largest percentage increases
AP - Wed Feb 19, 12:48PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
ANI Pharmaceuticals (ANIP) Jumps: Stock Adds 11.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 7:51AM CST
ANI Pharmaceuticals, Inc. was a big mover last session, as its shares rose nearly 12% on the day.
Why ANI Pharmaceuticals Inc. Shares Shot Higher
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 18, 1:00PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ANI Pharmaceuticals , a specialist in the...
ANI Pharmaceuticals Reports Record Net Revenues of $10.5 million, EPS from continuing operations of $0.35, and Adjusted Non-GAAP EBITDA of $3.9 Million for the Fourth Quarter Ended December 31, 2013
PR Newswire - Tue Feb 18, 7:30AM CST
ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today reported financial results for the three and twelve months ended December 31, 2013.
ANI Pharmaceuticals Schedules Conference Call for Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Thu Feb 06, 7:00AM CST
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its fourth quarter and full year 2013 financial results on Tuesday, February 18, 2014, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
ANI Pharmaceuticals Enters Development Agreement for Generic Drug Product with Sterling Pharmaceutical Services
PR Newswire - Mon Jan 06, 7:00AM CST
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), an emerging generic pharmaceutical company, today announced that it has entered into a fee-for-service development agreement for a generic drug product with Sterling Pharmaceutical Services ("Sterling.") The product will be developed by Sterling and transferred into ANI's facilities for commercial manufacture and marketing. The current annual market for this product is $60 million dollars, according to IMS Health.
Post-TEVA Deal, ANIP Shares Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 30, 3:37PM CST
Following the acquisition of several marketed generic drugs from Teva Pharmaceutical Industries Limited, ANI Pharmaceuticals shares gained.
Can The Uptrend Continue for ANI Pharmaceuticals (ANIP)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 9:43AM CDT
Can The Uptrend Continue for ANI Pharmaceuticals (ANIP)?
Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
ANI Pharmaceuticals concludes public offering at USD31.00 per share
M2 - Tue Mar 11, 7:14AM CDT
US-based pharmaceutical company ANI Pharmaceuticals (NasdaqGM:ANIP) revealed on Monday that it has closed its underwritten public offering of 1,612,903 shares of its common stock.
ANI Pharmaceuticals Presents at 26th Annual ROTH Conference
PR Newswire - Mon Mar 10, 4:00PM CDT
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) presented at the 26th Annual ROTH Conference at the Ritz-Carlton at Laguna Niguel, California. On March 10, 2014 at 11:30am PDT, Arthur S. Przybyl, President and CEO, gave the presentation, which was webcast live at http://wsw.com/webcast/roth28/anip. The live webcast was archived and will be available through the prior link for 90 days through June 8, 2014.
Regulatory Approvals, Pricing of Public Offering, Stock Price Movements, and Financial Reports - Analyst Notes on Arrowhead, ANI, OraSure, Rigel, and Foundation Medicine
PR Newswire - Mon Mar 10, 11:30AM CDT
Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), OraSure Technologies, Inc. (NASDAQ: OSUR), Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), and Foundation Medicine, Inc. (NASDAQ: FMI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
ANI Pharmaceuticals Announces Closing Of Public Offering Of Common Stock
PR Newswire - Mon Mar 10, 9:45AM CDT
ANI Pharmaceuticals, Inc. (the "Company") (NASDAQ: ANIP), today announced the closing of its previously announced underwritten public offering of 1,612,903 shares of common stock, at a price to the public of $31.00 per share and for gross proceeds of $50.0 million. The shares include 210,378 shares of common stock sold pursuant to the over-allotment option granted by ANI to the underwriters, which option was exercised in full. ANI expects net proceeds of the offering will be approximately $46.8 million, after deducting underwriting commissions and other offering expenses. Oppenheimer & Co. Inc. and Roth Capital Partners acted as joint book-running managers for the offering.
ANI Pharmaceuticals Expands Generic Drug Development Agreement with Sterling Pharmaceuticals
PR Newswire - Mon Mar 10, 7:00AM CDT
ANI Pharmaceuticals, (NASDAQ: ANIP), an emerging generic pharmaceutical company, today announced that it has entered into a fee for service product development agreement for an undisclosed generic drug product with Sterling Pharmaceutical Services ("Sterling"). The product will be developed by Sterling and transferred into ANI for commercial manufacture and marketing.
RestorGenex Names Stephen M. Simes as Chief Executive Officer
GlobeNewswire - Mon Mar 10, 6:13AM CDT
RestorGenex (OTCBB:SMDID) announced today that it has named Stephen M. Simes as its Chief Executive Officer, to lead the company. Mr. Simes formerly served as vice chairman, president, and CEO at BioSante Pharmaceuticals, Inc., a publicly held pharmaceutical company focused on developing products for women's and men's health and oncology that merged with ANI Pharmaceuticals, Inc. in 2013.
ANI Pharmaceuticals to Present at 26th Annual ROTH Conference
PR Newswire - Thu Mar 06, 9:45AM CST
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that its President and Chief Executive Officer, Arthur S. Przybyl, is scheduled to present at the 26th Annual ROTH Conference at the Ritz-Carlton at Laguna Niguel, California on Monday, March 10, 2014 at 11:30 a.m. Pacific Time. Charlotte C. Arnold, Vice President and Chief Financial Officer, will also be in attendance and representing ANI. Mr. Przybyl's presentation will be webcast live at http://wsw.com/webcast/roth28/anip, and archived and available through the link through June 8, 2014.
Strength Seen in ANI Pharmaceuticals, Inc. (ANIP): Stock Soars 15.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:44AM CST
ANI Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares surge 16% on the day.
ANI Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
PR Newswire - Wed Mar 05, 8:00AM CST
ANI Pharmaceuticals, Inc. (the "Company") (NASDAQ: ANIP) today announced that it has priced a firm commitment underwritten public offering of 1,402,525 shares of the Company's common stock at a purchase price to the public of $31.00 per share, resulting in net proceeds to the Company of $43.5 million (before estimated offering expenses payable by us). Oppenheimer & Co. Inc. and Roth Capital Partners are acting as joint book-running managers for the offering. The offering is expected to close on or about March 10, 2014, subject to customary closing conditions. The Company also granted the underwriters a 30-day option to purchase up to an additional 210,378 shares. The Company expects to use the net proceeds of the offering to research, develop, commercialize and expand its drug products, to acquire complementary businesses and technologies and for working capital and general corporate purposes.
ANI Pharmaceuticals Announces Proposed Public Offering Of Common Stock
PR Newswire - Tue Mar 04, 3:50PM CST
ANI Pharmaceuticals, Inc. (the "Company") (NASDAQ: ANIP) today announced that it intends to offer its common stock in a registered public offering pursuant to its existing shelf registration statement under the Securities Act of 1933, as amended. The Company also intends to grant the underwriters of the offering an option to purchase additional shares of common stock to cover over-allotments, if any. The Company plans to use the proceeds from the offering to research, develop, commercialize and expand its drug products, to acquire complementary businesses and technologies and for working capital and general corporate purposes. Oppenheimer & Co. Inc. and Roth Capital Partners are acting as joint book-running managers for the offering.
Surging Earnings Estimates Signal Good News for ANI Pharmaceuticals (ANIP) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 7:51AM CST
ANI Pharmaceuticals could be an interesting play for investors as it is witnessing solid activity on the earnings estimate revision front
Nasdaq stocks posting largest percentage increases
AP - Wed Feb 19, 12:48PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
ANI Pharmaceuticals (ANIP) Jumps: Stock Adds 11.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 7:51AM CST
ANI Pharmaceuticals, Inc. was a big mover last session, as its shares rose nearly 12% on the day.
Why ANI Pharmaceuticals Inc. Shares Shot Higher
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 18, 1:00PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ANI Pharmaceuticals , a specialist in the...
ANI Pharmaceuticals Reports Record Net Revenues of $10.5 million, EPS from continuing operations of $0.35, and Adjusted Non-GAAP EBITDA of $3.9 Million for the Fourth Quarter Ended December 31, 2013
PR Newswire - Tue Feb 18, 7:30AM CST
ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today reported financial results for the three and twelve months ended December 31, 2013.
ANI Pharmaceuticals Schedules Conference Call for Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Thu Feb 06, 7:00AM CST
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its fourth quarter and full year 2013 financial results on Tuesday, February 18, 2014, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
ANI Pharmaceuticals Enters Development Agreement for Generic Drug Product with Sterling Pharmaceutical Services
PR Newswire - Mon Jan 06, 7:00AM CST
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), an emerging generic pharmaceutical company, today announced that it has entered into a fee-for-service development agreement for a generic drug product with Sterling Pharmaceutical Services ("Sterling.") The product will be developed by Sterling and transferred into ANI's facilities for commercial manufacture and marketing. The current annual market for this product is $60 million dollars, according to IMS Health.
Post-TEVA Deal, ANIP Shares Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 30, 3:37PM CST
Following the acquisition of several marketed generic drugs from Teva Pharmaceutical Industries Limited, ANI Pharmaceuticals shares gained.
